Blueprint wins first FDA nod for a stomach cancer—though not exactly what it asked for

10th January 2020 Uncategorised 0

Blueprint Medicines won FDA approval for targeted therapy Ayvakit, a first-ever for the company and for the particular kind of stomach cancer it treats. But the green light wasn’t exactly what the company had hoped for—and that puts its plan to reach another subset of patients slightly behind rival Deciphera Pharmaceuticals.

More: Blueprint wins first FDA nod for a stomach cancer—though not exactly what it asked for
Source: fierce